Cargando…

Diversity in oat potential immunogenicity: basis for the selection of oat varieties with no toxicity in coeliac disease

BACKGROUND AND AIMS: Coeliac disease (CD) is triggered by an abnormal reaction to gluten. Peptides resulting from partially digested gluten of wheat, barley or rye cause inflammation of the small intestinal mucosa. Previous contradictory studies suggest that oats may trigger the abnormal immunologic...

Descripción completa

Detalles Bibliográficos
Autores principales: Comino, Isabel, Real, Ana, de Lorenzo, Laura, Cornell, Hugh, López-Casado, Miguel Ángel, Barro, Francisco, Lorite, Pedro, Torres, Ma Isabel, Cebolla, Ángel, Sousa, Carolina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Group 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112367/
https://www.ncbi.nlm.nih.gov/pubmed/21317420
http://dx.doi.org/10.1136/gut.2010.225268
_version_ 1782205732754554880
author Comino, Isabel
Real, Ana
de Lorenzo, Laura
Cornell, Hugh
López-Casado, Miguel Ángel
Barro, Francisco
Lorite, Pedro
Torres, Ma Isabel
Cebolla, Ángel
Sousa, Carolina
author_facet Comino, Isabel
Real, Ana
de Lorenzo, Laura
Cornell, Hugh
López-Casado, Miguel Ángel
Barro, Francisco
Lorite, Pedro
Torres, Ma Isabel
Cebolla, Ángel
Sousa, Carolina
author_sort Comino, Isabel
collection PubMed
description BACKGROUND AND AIMS: Coeliac disease (CD) is triggered by an abnormal reaction to gluten. Peptides resulting from partially digested gluten of wheat, barley or rye cause inflammation of the small intestinal mucosa. Previous contradictory studies suggest that oats may trigger the abnormal immunological response in patients with CD. Monoclonal antibodies (moAbs) against the main immunotoxic 33-mer peptide (A1 and G12) react strongly against wheat, barley and rye but have less reactivity against oats. The stated aim of this study is to test whether this observed reactivity could be related to the potential toxicity of oats for patients with CD. METHODS: In the present study, different oat varieties, controlled for their purity and by their distinct protein pattern, were used to examine differences in moAb G12 recognition by ELISA and western blot. Immunogenicity of oat varieties was determined by 33-mer concentration, T cell proliferation and interferon γ production. RESULTS: Three groups of oat cultivars reacting differently against moAb G12 could be distinguished: a group with considerable affinity, a group showing slight reactivity and a third with no detectable reactivity. The immunogenicity of the three types of oats as well as that of a positive and negative control was determined with isolated peripheral blood mononuclear T cells from patients with CD by measurement of cell proliferation and interferon γ release. A direct correlation of the reactivity with G12 and the immunogenicity of the different prolamins was observed. CONCLUSIONS: The results showed that the reactivity of the moAb G12 is proportional to the potential immunotoxicity of the cereal cultivar. These differences may explain the different clinical responses observed in patients suffering from CD and open up a means to identify immunologically safe oat cultivars, which could be used to enrich a gluten-free diet.
format Online
Article
Text
id pubmed-3112367
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BMJ Group
record_format MEDLINE/PubMed
spelling pubmed-31123672011-06-27 Diversity in oat potential immunogenicity: basis for the selection of oat varieties with no toxicity in coeliac disease Comino, Isabel Real, Ana de Lorenzo, Laura Cornell, Hugh López-Casado, Miguel Ángel Barro, Francisco Lorite, Pedro Torres, Ma Isabel Cebolla, Ángel Sousa, Carolina Gut Coeliac Disease BACKGROUND AND AIMS: Coeliac disease (CD) is triggered by an abnormal reaction to gluten. Peptides resulting from partially digested gluten of wheat, barley or rye cause inflammation of the small intestinal mucosa. Previous contradictory studies suggest that oats may trigger the abnormal immunological response in patients with CD. Monoclonal antibodies (moAbs) against the main immunotoxic 33-mer peptide (A1 and G12) react strongly against wheat, barley and rye but have less reactivity against oats. The stated aim of this study is to test whether this observed reactivity could be related to the potential toxicity of oats for patients with CD. METHODS: In the present study, different oat varieties, controlled for their purity and by their distinct protein pattern, were used to examine differences in moAb G12 recognition by ELISA and western blot. Immunogenicity of oat varieties was determined by 33-mer concentration, T cell proliferation and interferon γ production. RESULTS: Three groups of oat cultivars reacting differently against moAb G12 could be distinguished: a group with considerable affinity, a group showing slight reactivity and a third with no detectable reactivity. The immunogenicity of the three types of oats as well as that of a positive and negative control was determined with isolated peripheral blood mononuclear T cells from patients with CD by measurement of cell proliferation and interferon γ release. A direct correlation of the reactivity with G12 and the immunogenicity of the different prolamins was observed. CONCLUSIONS: The results showed that the reactivity of the moAb G12 is proportional to the potential immunotoxicity of the cereal cultivar. These differences may explain the different clinical responses observed in patients suffering from CD and open up a means to identify immunologically safe oat cultivars, which could be used to enrich a gluten-free diet. BMJ Group 2011-02-12 2011-07 /pmc/articles/PMC3112367/ /pubmed/21317420 http://dx.doi.org/10.1136/gut.2010.225268 Text en © 2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.
spellingShingle Coeliac Disease
Comino, Isabel
Real, Ana
de Lorenzo, Laura
Cornell, Hugh
López-Casado, Miguel Ángel
Barro, Francisco
Lorite, Pedro
Torres, Ma Isabel
Cebolla, Ángel
Sousa, Carolina
Diversity in oat potential immunogenicity: basis for the selection of oat varieties with no toxicity in coeliac disease
title Diversity in oat potential immunogenicity: basis for the selection of oat varieties with no toxicity in coeliac disease
title_full Diversity in oat potential immunogenicity: basis for the selection of oat varieties with no toxicity in coeliac disease
title_fullStr Diversity in oat potential immunogenicity: basis for the selection of oat varieties with no toxicity in coeliac disease
title_full_unstemmed Diversity in oat potential immunogenicity: basis for the selection of oat varieties with no toxicity in coeliac disease
title_short Diversity in oat potential immunogenicity: basis for the selection of oat varieties with no toxicity in coeliac disease
title_sort diversity in oat potential immunogenicity: basis for the selection of oat varieties with no toxicity in coeliac disease
topic Coeliac Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112367/
https://www.ncbi.nlm.nih.gov/pubmed/21317420
http://dx.doi.org/10.1136/gut.2010.225268
work_keys_str_mv AT cominoisabel diversityinoatpotentialimmunogenicitybasisfortheselectionofoatvarietieswithnotoxicityincoeliacdisease
AT realana diversityinoatpotentialimmunogenicitybasisfortheselectionofoatvarietieswithnotoxicityincoeliacdisease
AT delorenzolaura diversityinoatpotentialimmunogenicitybasisfortheselectionofoatvarietieswithnotoxicityincoeliacdisease
AT cornellhugh diversityinoatpotentialimmunogenicitybasisfortheselectionofoatvarietieswithnotoxicityincoeliacdisease
AT lopezcasadomiguelangel diversityinoatpotentialimmunogenicitybasisfortheselectionofoatvarietieswithnotoxicityincoeliacdisease
AT barrofrancisco diversityinoatpotentialimmunogenicitybasisfortheselectionofoatvarietieswithnotoxicityincoeliacdisease
AT loritepedro diversityinoatpotentialimmunogenicitybasisfortheselectionofoatvarietieswithnotoxicityincoeliacdisease
AT torresmaisabel diversityinoatpotentialimmunogenicitybasisfortheselectionofoatvarietieswithnotoxicityincoeliacdisease
AT cebollaangel diversityinoatpotentialimmunogenicitybasisfortheselectionofoatvarietieswithnotoxicityincoeliacdisease
AT sousacarolina diversityinoatpotentialimmunogenicitybasisfortheselectionofoatvarietieswithnotoxicityincoeliacdisease